UCLA Hematology/Oncology - Burbank

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Bladder cancer3 trials
• Metastatic breast cancer2 trials
• Gastric and oesophageal cancer1 trial
• Kidney cancer1 trial
• Lung cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 34 trials
• Phase 1/22 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Recruiting5 trials
• Active, not recruiting2 trials
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• Pfizer5 trials
• Seagen, a wholly owned subsidiary of Pfizer4 trials

Running trials

• Recruiting

  Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  NCT07392892· Phase 2/3· Pfizer· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Pfizer· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Active, not recruiting

  Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer2 recruiting
• Gastric and oesophageal cancer1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source